2015
DOI: 10.1590/abd1806-4841.20153818
|View full text |Cite
|
Sign up to set email alerts
|

Syndrome in question

Abstract: Morbihan Syndrome is a rare entity with unknown etiology. It is clinically characterized by chronic erythematous edema on the face - especially in the middle and upper third of the face - and creates abnormal facial contours that are initially intermitent but become permanent with the development of the syndrome. The histopathology is nonspecific and its therapy is a major challenge due to poor response to the various treatment options. We present the case of a male patient with a five-month-history of disease. Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
5
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 10 publications
0
5
0
Order By: Relevance
“…2 Doxycycline in doses of 200 mg/day for 4-12 months was successful in five patients 3,4 but was ineffective in short duration treatment schedules irrespective of the histological presence of mast cell infiltration. 5,6 The small number and intrafollicular location of Demodex mites in our case could not validate the diagnosis of granulomatous rosacea-like demodicidosis. 7 The subantimicrobial dose of 40 mg/d doxycycline monohydrate is not associated with the side-effects of long-term high doses or the risk of resistance.…”
mentioning
confidence: 61%
See 1 more Smart Citation
“…2 Doxycycline in doses of 200 mg/day for 4-12 months was successful in five patients 3,4 but was ineffective in short duration treatment schedules irrespective of the histological presence of mast cell infiltration. 5,6 The small number and intrafollicular location of Demodex mites in our case could not validate the diagnosis of granulomatous rosacea-like demodicidosis. 7 The subantimicrobial dose of 40 mg/d doxycycline monohydrate is not associated with the side-effects of long-term high doses or the risk of resistance.…”
mentioning
confidence: 61%
“…5 We submitted the sample to immunohistochemistry using anti-COX-2 antibody (ST21; Cell Marque, Rocklin, USA; 1 : 1000; 60') and performed a semiquantitative analysis (0%score 0, negative; <20%score 1, low; 20-50%score 2, moderate; >50%score 3, high). 6 Pearson's chi-square, Fisher exact and nonparametric Mann-Whitney tests were used for statistical analysis, with a 5% level of significance.…”
Section: Editormentioning
confidence: 99%
“…It can inhibit mast cell degranulation during the early stages of inflammation. It suppresses pathological edema and fibrosis by reducing the release of inflammatory factors IgE, tumor necrosis factor-α, interleukin (IL)-4, and IL-13[ 17 , 18 ]. The success of the combination therapy of minocycline and ketotifen in our patient may be a good option that reduces the duration of antibiotic administration, especially in the early stages of the disease.…”
Section: Discussionmentioning
confidence: 99%
“…On the contrary, combination therapy with minocycline and tranilast given in a patient with no presence of mast cell infiltrates in histology remained ineffective (Nagasaka et al, ). Promising results have been demonstrated after long‐term isotretinoin monotherapy or systemic combination of isotretinoin with ketotifen (Smith & Cohen, ; Kabuto, Fujimoto, Honda, & Tanaka, ; Mazzatenta, Giorgino, Rubegni, Aloe, & Fimiani, ; Rebellato, Rezende, Battaglin, Lima, & Fillus Neto, ). Isotretinoin's mechanism of action in MD is postulated to be correlated with its anti‐inflammatory and immunomodulatory properties that make it also useful in treatment of rosacea (Smith & Cohen, ).…”
Section: Discussionmentioning
confidence: 99%